NASDAQ:PCRXPacira Biosciences Competitors & Alternatives

Johnson & Johnson (NYSE:JNJ) and Pacira Biosciences (NASDAQ:PCRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Insider & Institutional Ownership

68.5% of Johnson & Johnson shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by insiders. Comparatively, 5.8% of Pacira Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Johnson & Johnson and Pacira Biosciences' top-line revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Pacira Biosciences. Johnson & Johnson is trading at a lower price-to-earnings ratio than Pacira Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Johnson & Johnson has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Pacira Biosciences has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Johnson & Johnson and Pacira Biosciences, as reported by MarketBeat.com.

Johnson & Johnson presently has a consensus target price of $163.8571, indicating a potential upside of 16.24%. Pacira Biosciences has a consensus target price of $56.1429, indicating a potential upside of 7.20%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, research analysts clearly believe Johnson & Johnson is more favorable than Pacira Biosciences.

Profitability

This table compares Johnson & Johnson and Pacira Biosciences' net margins, return on equity and return on assets.

Summary

Johnson & Johnson beats Pacira Biosciences on 11 of the 14 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Pacira Biosciences (NASDAQ:PCRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

74.3% of Merck & Co., Inc. shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 5.8% of Pacira Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Merck & Co., Inc. and Pacira Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Merck & Co., Inc. has higher revenue and earnings than Pacira Biosciences. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Pacira Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Merck & Co., Inc. has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Pacira Biosciences has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Merck & Co., Inc. and Pacira Biosciences, as reported by MarketBeat.

Merck & Co., Inc. presently has a consensus target price of $94.1538, indicating a potential upside of 19.51%. Pacira Biosciences has a consensus target price of $56.1429, indicating a potential upside of 7.20%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts plainly believe Merck & Co., Inc. is more favorable than Pacira Biosciences.

Profitability

This table compares Merck & Co., Inc. and Pacira Biosciences' net margins, return on equity and return on assets.

Summary

Merck & Co., Inc. beats Pacira Biosciences on 11 of the 14 factors compared between the two stocks.

Pacira Biosciences (NASDAQ:PCRX) and Pfizer (NYSE:PFE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Pacira Biosciences and Pfizer, as provided by MarketBeat.com.

Pacira Biosciences currently has a consensus price target of $56.1429, indicating a potential upside of 7.20%. Pfizer has a consensus price target of $38.6083, indicating a potential upside of 11.88%. Given Pfizer's higher probable upside, analysts plainly believe Pfizer is more favorable than Pacira Biosciences.

Insider and Institutional Ownership

70.3% of Pfizer shares are held by institutional investors. 5.8% of Pacira Biosciences shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Pacira Biosciences has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500.

Profitability

This table compares Pacira Biosciences and Pfizer's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Pacira Biosciences and Pfizer's gross revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Pacira Biosciences. Pfizer is trading at a lower price-to-earnings ratio than Pacira Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Pfizer beats Pacira Biosciences on 9 of the 14 factors compared between the two stocks.

Pacira Biosciences (NASDAQ:PCRX) and Eli Lilly And Co (NYSE:LLY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for Pacira Biosciences and Eli Lilly And Co, as provided by MarketBeat.com.

Pacira Biosciences currently has a consensus price target of $56.1429, indicating a potential upside of 7.20%. Eli Lilly And Co has a consensus price target of $169.7273, indicating a potential upside of 3.57%. Given Pacira Biosciences' higher probable upside, equities research analysts plainly believe Pacira Biosciences is more favorable than Eli Lilly And Co.

Insider and Institutional Ownership

77.4% of Eli Lilly And Co shares are held by institutional investors. 5.8% of Pacira Biosciences shares are held by insiders. Comparatively, 0.1% of Eli Lilly And Co shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Pacira Biosciences has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Eli Lilly And Co has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Profitability

This table compares Pacira Biosciences and Eli Lilly And Co's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Pacira Biosciences and Eli Lilly And Co's gross revenue, earnings per share and valuation.

Eli Lilly And Co has higher revenue and earnings than Pacira Biosciences. Eli Lilly And Co is trading at a lower price-to-earnings ratio than Pacira Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Eli Lilly And Co beats Pacira Biosciences on 11 of the 15 factors compared between the two stocks.

Pacira Biosciences (NASDAQ:PCRX) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Volatility & Risk

Pacira Biosciences has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Pacira Biosciences and AbbVie, as provided by MarketBeat.

Pacira Biosciences currently has a consensus price target of $56.1429, indicating a potential upside of 7.20%. AbbVie has a consensus price target of $106.80, indicating a potential upside of 8.01%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Pacira Biosciences.

Insider & Institutional Ownership

72.4% of AbbVie shares are owned by institutional investors. 5.8% of Pacira Biosciences shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pacira Biosciences and AbbVie's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Pacira Biosciences and AbbVie's gross revenue, earnings per share and valuation.

AbbVie has higher revenue and earnings than Pacira Biosciences. AbbVie is trading at a lower price-to-earnings ratio than Pacira Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Pacira Biosciences on 10 of the 14 factors compared between the two stocks.

Pacira Biosciences (NASDAQ:PCRX) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Volatility & Risk

Pacira Biosciences has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Pacira Biosciences and Bristol-Myers Squibb, as provided by MarketBeat.

Pacira Biosciences currently has a consensus price target of $56.1429, indicating a potential upside of 7.20%. Bristol-Myers Squibb has a consensus price target of $68.1667, indicating a potential upside of 15.26%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Pacira Biosciences.

Insider & Institutional Ownership

74.2% of Bristol-Myers Squibb shares are owned by institutional investors. 5.8% of Pacira Biosciences shares are owned by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pacira Biosciences and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Pacira Biosciences and Bristol-Myers Squibb's gross revenue, earnings per share and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Pacira Biosciences. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Pacira Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol-Myers Squibb beats Pacira Biosciences on 11 of the 14 factors compared between the two stocks.